Cytek Biosciences, Inc.
US ˙ NasdaqGS ˙ US23285D1090

Introduction

This page provides a comprehensive analysis of the known insider trading history of Patrick Jeanmonod. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Patrick Jeanmonod has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CTKB / Cytek Biosciences, Inc. CHIEF FINANCIAL OFFICER 97,465
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Patrick Jeanmonod. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CTKB / Cytek Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CTKB / Cytek Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CTKB / Cytek Biosciences, Inc. Insider Trades
Insider Sales CTKB / Cytek Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CTKB / Cytek Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CTKB / Cytek Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Patrick Jeanmonod as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-03-13 2024-03-11 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -1,912 97,465 -1.92 7.22 -13,805 703,697
2024-03-13 2024-03-11 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 4,908 99,377 5.20
2024-02-22 2024-02-20 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -683 94,469 -0.72 8.38 -5,724 791,650
2024-02-22 2024-02-20 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 1,752 95,152 1.88
2023-12-27 2023-12-26 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 93,400 -3.11 9.50 -28,500 887,300
2023-11-27 2023-11-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 96,400 -3.02 6.94 -20,820 669,016
2023-11-21 2023-11-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -1,434 99,400 -1.42 5.98 -8,575 594,412
2023-11-21 2023-11-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 3,681 100,834 3.79
2023-11-21 2023-11-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -683 97,153 -0.70 5.98 -4,084 580,975
2023-11-21 2023-11-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 1,752 97,836 1.82
2023-10-25 2023-10-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 96,084 -3.03 4.68 -14,040 449,673
2023-09-26 2023-09-25 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 99,084 -2.94 6.38 -19,140 632,156
2023-08-28 2023-08-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 102,084 -2.85 7.69 -23,070 785,026
2023-08-21 2023-08-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -1,434 105,084 -1.35 8.46 -12,132 889,011
2023-08-21 2023-08-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 3,681 106,518 3.58
2023-08-21 2023-08-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -683 102,837 -0.66 8.46 -5,778 870,001
2023-08-21 2023-08-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 1,752 103,520 1.72
2023-07-25 2023-07-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X 3,000 101,768 3.04 9.17 27,510 933,213
2023-06-27 2023-06-26 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 104,768 -2.78 7.96 -23,880 833,953
2023-05-25 2023-05-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 107,768 -2.71 7.76 -23,280 836,280
2023-05-19 2023-05-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -956 110,768 -0.86 6.69 -6,396 741,038
2023-05-19 2023-05-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 2,454 111,724 2.25
2023-05-19 2023-05-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -683 109,270 -0.62 6.69 -4,569 731,016
2023-05-19 2023-05-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 1,752 109,953 1.62
2023-04-25 2023-04-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 108,201 -2.70 10.24 -30,720 1,107,978
2023-03-24 2023-03-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 111,201 -2.63 8.33 -24,990 926,304
2023-02-28 2023-02-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,000 114,201 -2.56 11.05 -33,150 1,261,921
2023-02-23 2022-09-08 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 40,000 116,132 52.54 0.40 16,000 46,453
2023-02-23 2023-02-21 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -683 117,201 -0.58 10.97 -7,493 1,285,695
2023-02-23 2023-02-21 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 1,752 117,884 1.51
2023-01-25 2023-01-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,500 76,132 -4.40 11.05 -38,675 841,259
2022-12-29 2022-12-27 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,500 79,632 -4.21 9.77 -34,195 778,005
2022-11-28 2022-11-25 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,500 83,132 -4.04 14.30 -50,050 1,188,788
2022-11-22 2022-11-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -683 86,632 -0.78 14.75 -10,074 1,277,822
2022-11-22 2022-11-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 1,752 87,315 2.05
2022-10-25 2022-10-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,500 85,563 -3.93 15.16 -53,060 1,297,135
2022-09-28 2022-09-26 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,500 89,063 -3.78 12.63 -44,205 1,124,866
2022-08-25 2022-08-24 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,500 92,563 -3.64 13.45 -47,075 1,244,972
2022-08-19 2022-08-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -683 96,063 -0.71 14.06 -9,603 1,350,646
2022-08-19 2022-08-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 1,752 96,746 1.84
2022-08-03 2022-08-01 4 CTKB Cytek Biosciences, Inc.
Common Stock
S - Sale X -3,500 94,994 -3.55 12.80 -44,800 1,215,923
2022-05-20 2022-05-18 4 CTKB Cytek Biosciences, Inc.
Restricted Stock Units
M - Exercise -2,336 25,706 -8.33
2022-05-20 2022-05-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
F - Taxes -910 97,423 -0.93 9.65 -8,782 940,132
2022-05-20 2022-05-18 4 CTKB Cytek Biosciences, Inc.
Common Stock
M - Exercise 2,336 98,333 2.43
2022-03-02 2022-02-28 4 CTKB Cytek Biosciences, Inc.
Restricted Stock Units
A - Award 28,042 28,042
2022-03-02 2022-02-28 4 CTKB Cytek Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 42,310 42,310
2021-07-26 2021-07-22 4 CTKB Cytek Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 125,000 125,000
2021-07-22 3 CTKB Cytek BioSciences, Inc.
Common Stock
95,997
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)